|
Keywords
|
Cancer Diagnosis, Gene and Cancer, Cancer Risks, Cancer Genetics, Solid Tumors
|
|
Abstract
|
Abstract
Single-nucleotide substitution of FAS (rs2234767) may alter the expression of FAS gene. Recent
evidence suggests association of this polymorphism with increased risk of various cancers. Therefore,
this study aimed to assess the FAS promoter polymorphism (rs2234767) in thyroid cancer susceptibility
in the northwestern population of Iran. Genotypes of 106 patients with thyroid cancer and 186
controls were determined for the FAS-1377G>A polymorphism by Tetra-ARMS-PCR. For statistical
analysis, p<0.05 was considered as significance level. None of the genotypes of FAS-1377G/A
polymorphism were associated with the risk of thyroid cancer, significantly (p>0.05). The frequency of
the homozygous genotype (GG) in patients was higher rather than controls (72.64% and 65.59%,
respectively). In contrast, the heterozygous genotype frequency in controls was about 5% higher rather
than cases (OR=0.751, 95%CI=0.422-1.331, p=0.296). There was higher but not significant frequency
for AA genotype in controls than cases (3.76% and 1.88%, respectively). According to our findings, the
FAS-1377G>A polymorphism cannot be used as a molecular marker to predict thyroid cancer in the
northwestern population of Iran.
|